Isolation, identification, and carriage of candidal species in PHLAs and their correlation with immunological status in cases with and without HAART

Journal of Oral and Maxillofacial Pathology

Volumn 16, Issue 1, 2012, Pages 38-44

  Chandra Kantheti, Lalith Prakash ^a   Reddy, B V R ^a   Ravikumar, Shamala ^a   Anuradha, C H ^a   Chandrasekhar, P ^a   Raja Rajeswari, M ^b  

^a SIBAR Institute of Dental Sciences ^*  (India)

^b Guntur Medical College   (India)

Author keywords

Candida albicans; highly active antiretroviral therapy; human immunodeficiency virus; oral candidiasis

Indexed keywords

EID: 84857884476     PISSN: 0973029X     EISSN: 1998393X     Source Type: Journal    
DOI: 10.4103/0973-029X.92971     Document Type: Article

References (34)

1. Willey JM, Sherwood LM, Woolverton CJ. Prescott, Harley and Klein's Microbiology. 7 th ed New York: McGraw Hill; 2008. p. 925-30.
2. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001;183:286-93. (Pubitemid 32066031)
3. Xu J, Mitchell TG. Geographical differences in human oral yeast flora. Clin Infect Dis 2003;36:221-4. (Pubitemid 36143422)
4. McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due to Candida krusei: Report of 10 cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992;14:472-8.
5. Fidel PL Jr, Vazquez JA, Sobel JD. Candid aglabrata: Review of epidemiology, pathogenesis, and clinicaldiseasewithcomparisonto C. albicans. Clin Microbiol Rev 1999;12:80-96.
6. Reznik DA, Daniels CO. RN-BC, HIV Dent-Oral Manifestations. Available from: http://www.hivdent.org/-oralmanifestations. [Last accessed 2007].
7. Milne LJ. Fungi, Mackie and McCartney Practical Medical Microbiology. In: Collee JG, editor. 14 th ed, Vol. 2. Chapter 41. Edinburgh: Churchill Livingstone; 1996. p. 695-717.
8. Rippon JW. Candidiasis and the Pathogenic Yeasts. Medical Mycology. 3 rd ed. Philadelphia: W.B. Saunders; 1998. p. 536-81.
9. Shaheen MA, Taha M. Species Identification of Candida isolates obtained from oral lesions of Hospitalized and Non-hospitalized patients with Oral Candidiasis. Egypt Dermatol J 2006;2:14.
10. Cohen R, Roth FJ, Delgado E, Ahearn DG, Kalser MH. Fungal flora of the normal human small and large intestine. N Engl J Med 1969;280:638-41.
11. Campo J, Del Romero J, Castilla J, García S, Rodríguez C, Bascones AOral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002;31:5-10. (Pubitemid 34535942)
12. Al-Abeid HM, Abu-Elteen KH, Elkarmi AZ, Hamad MA. Isolation and characterization of Candida spp. in Jordanian cancer patients: Prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis 2004;57:279-84. (Pubitemid 40260248)
13. Zaremba ML, Daniluk T, Rozkiewicz D, Cylwik-Rokicka D, Kierklo A, Tokajuk G, et al. Incidence rate of Candida species in the oral cavity of middle-aged and elderly subjects. Adv Med Sci 2006;51 Suppl 1:233-6.
14. Dignani MC, Joseph Solomkin, Anaisse EJ. Candida. In: Anaisse, McGinnis, Pfaller, editors. Textbook of Clinical Mycology. 1 st ed. Chapter 8. Philadelphia: Churchill Livingstone; 2003. p. 195-239.
15. Schmidt-WesthausenAM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 2000;29:336-41. (Pubitemid 30459306)
16. Teanpaisan R, Nittyananta W. Prevalence of Candida species in AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 1998;27:4-7. (Pubitemid 28059160)
17. Tsang CS, Samaranayake LP. Oral yeasts and coliforms in HIV-infected individuals in Hong Kong. Mycoses 2000;43:303-8.
18. Kerdpon D, Pongsiriwet S, Pangsomboon K, Iamaroon A, Kampoo K, Sretrirutchai S, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Dis 2004;10:138-44. (Pubitemid 39090098)
19. Patel M, Shackleton JT, Coogan MM. Effect of antifungal treatment on the prevalence of yeasts in HIV-infected subjects. J Med Microbiol 2006;55:127-84.
20. Belazi M, Velegraki A, Fleva A, Gidarakou I, Papanaum L, Baka D, et al. Candidal overgrowth in diabetic patients: Potential predisposing factors. Mycoses 2005;48:192-6. (Pubitemid 40592852)
21. Ikebe K, Morii K, Matsuda K, Hata K, Nokubi T. Association of candidal activity with denture use and salivary flow in symptom-free adults over 60 years. J Oral Rehabil 2006;33:36-42. (Pubitemid 43478999)
22. Ranganathan K, Devi MU, Saraswathi TR, Kumarasamy N, Solomon S, Johnson N. Oral Lesions and Conditions Associated with Human Immunodeficiency Virus Infection in 1000 South Indian Patients. Ann Acad Med Singapore 2004;33 (Suppl):37s-42s. (Pubitemid 39471905)
23. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clinic North Am 2002;16:915-33. (Pubitemid 35477519)
24. Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J ClinMicrobiol 1996;34:58-61. (Pubitemid 126506893)
25. Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with Human immunodeficiency virus infection in 300 south Indian patients. Oral Dis 2000;6:152-7. (Pubitemid 30340641)
26. Qi QG, Hu T, Zhou XD. Frequency of species and Molecular Characterization of Oral Candida and Distribution in Host of different ages in China. J Oral Pathol Med 2005;34:350-6.
27. Dorko E, Pilipcinec E, Tkacikova L. Incidence of Candida tropicalis in Clinical Samples over 5 year period. Pak J BiolSci 2000;3:606-9.
28. Imam N, Carpenter CC, Mayer KH, Fisher A, Stein M, Danforth SB. Hierarchical pattern of mucosal candida infections in HIV-seropositive women. Am J Med 1990;89:142-6. (Pubitemid 20254437)
29. Fichtenbaum CJ, Powderley WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998;26:556-65. (Pubitemid 28155000)
30. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, et al. Evolution pattern of HIV replication and distribution in lymph nodes following primary infection: Implications for anti-viral therapy. Nat Med 1998;4:341-5. (Pubitemid 28144095)
31. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-53. (Pubitemid 30256327)
32. Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999;41:227-34. (Pubitemid 29243825)
33. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001;9:327-35. (Pubitemid 32575277)
34. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 2000;89:299-304.